Current status of prognostication in classical Hodgkin lymphoma
Author:
Affiliation:
1. Department of Pathology; Section of Hematopathology; The University of Chicago Medicine; Chicago IL USA
2. First Department of Internal Medicine; University Hospital Cologne; Cologne Germany
3. German Hodgkin Study Group (GHSG); Cologne Germany
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12759/fullpdf
Reference107 articles.
1. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells;Alvaro;Clinical Cancer Research,2005
2. Defining a Hodgkin Lymphoma Population for Novel Therapeutics after Relapse from Autologous Hematopoietic Cell Transplantation;Arai;Leukaemia & Lymphoma,2013
3. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation;Bashey;Blood,2009
4. The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22);Bennett;Clinical Radiology,1983
5. State of the art in the treatment of Hodgkin lymphoma;Borchmann;Nature Reviews. Clinical oncology,2012
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma;International Journal of Molecular Sciences;2023-08-24
2. Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease;Frontiers in Pharmacology;2021-06-18
3. SNPs in genes encoding for IL-10, TNF-α, and NFκB p105/p50 are associated with clinical prognostic factors for patients with Hodgkin lymphoma;PLOS ONE;2021-03-08
4. Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma;Oncohematology;2020-12-07
5. Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma;Cancers;2020-12-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3